Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024
-
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting
-
CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates
-
CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Musc
-
CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
-
CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates
-
CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec
-
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab
-
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab
-
CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates